- PIPELINE
- COMPANY
- NEWS & PUBLICATIONS
- Company news
- Micar 21 Ltd started to provide to customers discovery of novel active substances for medicinal cosmetics development.
- New! A pioneering study focused on the prevention of hypertrophic cardiomyopathy (HCM) among individuals with a sarcomere gene mutation (Feb. 2015)
- Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
- Structural and Dynamical Insight into PPARγ
- Try our outsourcing services!
- Identification of P-glycoprotein binders based on in house prepared diverse set of structures
- PPARγ helix 12 exhibits an antagonist conformation
- PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
- Micar Innovation (Micar21) TOP 8 BioTech Award by Delta Ventures and the TOP 50 of the 2018 Startup World Cup & Summit Regional Finals!
- Diplomatic World
- Micar Innovation listed as a Emerging Players
- Micar Innovation is One of 250 Companies
- Micar Innovation (Micar21) is the winner of а prestigious award for Innovative enterprise of the year 2018
- AI for Drug Discovery Biomarker Development
- Discovery of the first class of dual CCR5/7 antagonists for COVID-19
- Covid B.1.1.529
- Scientific publications
- Combination of Genetic Screening and Molecular Dynamics as a Useful Tool for Identification of Disease-Related Mutations: ZASP PDZ Domain G54S Mutation Case
- Structural insight into the UNC-45–myosin complex
- Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
- Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study
- Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
- Structural and Dynamical Insight into PPARγ Antagonism: In silico Study of the Ligand-Receptor Interactions of non-Covalent Antagonists
- Molecular dynamics simulation of the human estrogen receptor alpha: contribution to the pharmacophore of the agonists
- PPARγ helix 12 exhibits an antagonist conformation
- PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
- Prediction of Accurate Binding Modes using Combination of classical and accelerated Molecular dynamics and Free Energy Perturbation Calculations: An Application to Toxicity Studies
- An Improvement of the Free Energy Perturbation (FEP+) Sampling Protocol in Case of Flexible protein Ligand Binding Sites
- Combination of Structural based Pharmacophore and Docking Virtual Screens: An Efficient Structure-based Protocol for Lead Identification
- Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies
- Discovery of New Classes of Glycine transporter 2 (GlyT2) Inhibitors and GlyT2 Selectivity Studies
- Discovery of New AKT1 Inhibitors by Combination of In silico Structure Based Virtual Screening Approaches and Biological Evaluations
- N501Y_mutation_manuscript
- N501Y and K417N mutation manuscript
- Achievements & Awards
- Interview in the news
- Analytics reports
- Events
- Company news
- Micar Innovation (Micar21)
- 38A, Karamfil street
- 1616, Sofia, Bulgaria
- info@micar21.com
- www.micar21.com
- +359 888 531345
Micar21 (Micar Innovation) © 2016 - 2024 All rights reserved.